(Created page with "{{Infobox drug reference | trade_names =Bridion | drug_class = | drug_class_color =neuromuscular_blocker_reversal | uses =Reversal of neuromuscular blockade from Rocuroni...")
 
m (Added embedded dosage calculation)
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Infobox drug reference
{{Infobox drug reference
| trade_names =Bridion  
| trade_names = Bridion
| drug_class =  
| drug_class =  
| drug_class_color =neuromuscular_blocker_reversal  
| drug_class_color = neuromuscular_blocker_reversal
| uses =Reversal of neuromuscular blockade from [[Rocuronium|rocuronium]] and [[Vecuronium|vecuronium]]  
| uses = Reversal of neuromuscular blockade from [[Rocuronium|rocuronium]] and [[Vecuronium|vecuronium]]
| contraindications =Renal impairment  
| contraindications = Renal impairment
| routes =Intravenous  
| routes = Intravenous
| dosage =Based upon response to train-of-four stimulation:
| dosage =  
 
| halflife_elimination =  
* 2+ twitches: 2 mg/kg
| formula = C<sub>72</sub>H<sub>112</sub>O<sub>48</sub>S<sub>8</sub>
* 1-2 posttetanic twitches: 4 mg/kg
| image_file = Sugammadex.svg
<br/>
| protein_binding =  
Reversal immediately after administration of rocuronium 1.2 mg/kg: 16 mg/kg
| clearance =  
|halflife_elimination=|formula=C<sub>72</sub>H<sub>112</sub>O<sub>48</sub>S<sub>8</sub>|image_file=Sugammadex.svg|protein_binding=|clearance=|time_onset=|halflife_redistribution=|metabolism=|duration=|adverse_effects=Bradycardia, may interfere with hormonal contraceptives|mechanism=Encapsulation of rocuronium or vecuronium|molar_mass=2002.12 g/mol}}
| time_onset =  
 
| halflife_redistribution =  
| metabolism =  
| duration =  
| adverse_effects = Bradycardia, may interfere with hormonal contraceptives
| dosage_calculation = sugammadex
| mechanism = Encapsulation of rocuronium or vecuronium
| molar_mass = 2002.12 g/mol
}}
'''Sugammadex''' is used to reverse neuromuscular blockade from [[rocuronium]] and [[vecuronium]].
'''Sugammadex''' is used to reverse neuromuscular blockade from [[rocuronium]] and [[vecuronium]].


==Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. -->==
==Uses<!-- Describe uses of the drug. If appropriate, add subsections for each indication. -->==
If a patient requires reparaylsis after administration of sugammadex (up to 4 mg/kg), rocuronium or vecuronium can be re-administered after a minimum waiting time.<ref>{{Cite web|last=|first=|date=|title=BRIDION® (sugammadex) Injection Drug Label (FDA)|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022225lbl.pdf|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>
{| class="wikitable"
|+
!Drug and dose to be administered
!Minimum waiting time
|-
|Rocuronium 1.2 mg/kg
|5 minutes
|-
|Rocuronium 0.6 mg/kg or
vecuronium 0.1 mg/kg
|4 hours
|}


==Contraindications<!-- List contraindications and precautions for use of the drug. -->==
==Contraindications<!-- List contraindications and precautions for use of the drug. -->==


===Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. -->===
===Absolute contraindications<!-- List absolute contraindications for use of the drug. If none, this section may be removed. -->===
* Previous anaphylactic reaction to sugammadex


===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->===
===Precautions<!-- List precautions for use of the drug. If none, this section may be removed. -->===
* Sugammadex can also bind steroid-structured molecules such as estrogen and tamoxifen. Consideration to using other agents to reverse NMB should be given to those patients on tamoxifen or toremifene for breast cancer. Female patients of child-bearing age on oral birth control should be advised of the potential of a short-term decrease in the efficacy of this method of birth control following reversal with sugammadex.
* Renal disease is a relative contraindication to the use of sugammadex as it is mainly renally cleared. With decreased renal clearance, the drug will stay in the body longer and the safety profile of this kind of drug exposure has not been well studied.


==Pharmacology==
==Pharmacology==
Line 39: Line 64:


==References==
==References==
<references />
[[Category:Drug reference]]
[[Category:Antidotes]]
[[Category:Neuromuscular blocker reversal agents]]

Latest revision as of 00:34, 30 March 2022

Sugammadex
Trade names

Bridion

Sugammadex.svg
Clinical data
Uses

Reversal of neuromuscular blockade from rocuronium and vecuronium

Contraindications

Renal impairment

Routes of administration

Intravenous

Dosage
Pharmacodynamics
Mechanism of action

Encapsulation of rocuronium or vecuronium

Adverse effects

Bradycardia, may interfere with hormonal contraceptives

Pharmacokinetics
Physical and chemical data
Formula

C72H112O48S8

Molar mass

2002.12 g/mol

Article quality
Editor rating
In development
User likes
0

Sugammadex is used to reverse neuromuscular blockade from rocuronium and vecuronium.

Uses

If a patient requires reparaylsis after administration of sugammadex (up to 4 mg/kg), rocuronium or vecuronium can be re-administered after a minimum waiting time.[1]

Drug and dose to be administered Minimum waiting time
Rocuronium 1.2 mg/kg 5 minutes
Rocuronium 0.6 mg/kg or

vecuronium 0.1 mg/kg

4 hours

Contraindications

Absolute contraindications

  • Previous anaphylactic reaction to sugammadex

Precautions

  • Sugammadex can also bind steroid-structured molecules such as estrogen and tamoxifen. Consideration to using other agents to reverse NMB should be given to those patients on tamoxifen or toremifene for breast cancer. Female patients of child-bearing age on oral birth control should be advised of the potential of a short-term decrease in the efficacy of this method of birth control following reversal with sugammadex.
  • Renal disease is a relative contraindication to the use of sugammadex as it is mainly renally cleared. With decreased renal clearance, the drug will stay in the body longer and the safety profile of this kind of drug exposure has not been well studied.

Pharmacology

Pharmacodynamics

Mechanism of action

Adverse effects

Pharmacokinetics

Chemistry and formulation

History

References

  1. "BRIDION® (sugammadex) Injection Drug Label (FDA)" (PDF).